Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis

Sampaio-Barros, Percival Degrava; Andrade, Danieli; Seguro, L; Pasoto, Sandra Gofinet; Viana, Vilma Santos Trindade; Ribeiro, Ana C.; Aikawa, Nádia E.; Timenetsky, María do Carmo Sampaio Tavares; Precioso, Alexander Roberto; Silva, Clóvis A.; Bonfá, Eloísa

doi:10.1093/rheumatology/kex330

Cited by 11 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the pandemic monovalent subunit influenza vaccine, most larger studies report reduced immunogenicity in patients with AIIRD (mostly RA and SLE), although protective antibody levels were reached in the majority of patients 41 52 54–68. A second booster dose of vaccine, given 3–4 weeks after the first, improved immunogenicity, resulting in seroprotection levels comparable to those of HCs 55 62 69.…”

Section: Resultsmentioning

confidence: 99%

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

et al. 2019

View full text Add to dashboard Cite

AimTo present a systematic literature review (SLR) on efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD), aiming to provide a basis for updating the EULAR evidence-based recommendations.MethodsAn SLR was performed according to the standard operating procedures for EULAR-endorsed recommendations. Outcome was determined by efficacy, immunogenicity and safety of vaccination in adult patients with AIIRD, including those receiving immunomodulating therapy. Furthermore, a search was performed on the effect of vaccinating household members of patients with AIIRD on the occurrence of vaccine-preventable infections in patients and their household members (including newborns). The literature search was performed using Medline, Embase and the Cochrane Library (October 2009 to August 2018).ResultsWhile most investigated vaccines were efficacious and/or immunogenic in patients with AIIRD, some were less efficacious than in healthy control subjects, and/or in patients receiving immunosuppressive agents. Adverse events of vaccination were generally mild and the rates were comparable to those in healthy persons. Vaccination did not seem to lead to an increase in activity of the underlying AIIRD, but insufficient power of most studies precluded arriving at definite conclusions. The number of studies investigating clinical efficacy of vaccination is still limited. No studies on the effect of vaccinating household members of patients with AIIRD were retrieved.ConclusionEvidence on efficacy, immunogenicity and safety of vaccination in patients with AIIRD was systematically reviewed to provide a basis for updated recommendations.

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Side effects in some cases were reported to even be less frequent in SSc than in healthy control, although not significantly [19]. For instance, Sampaio-Barros et al reported local side effects in 7.6% of SSc vs. 10.9% of controls and minor systemic reactions rates in 25% vs. 31.5% in SSc and controls, respectively [19].…”

Section: Efficacy and Safety Of Anti-influenza And Antipneumococcal Vaccinementioning

confidence: 99%

“…In addition, no severe collateral effects [19,21,22] and no disease flares were reported [20]. Local and mild side effects in AID, including SSc, are comparable to those in the healthy subject [19,22,23]. Side effects in some cases were reported to even be less frequent in SSc than in healthy control, although not significantly [19].…”

Section: Efficacy and Safety Of Anti-influenza And Antipneumococcal Vaccinementioning

confidence: 99%

“…Different studies showed that SSc patients develop seroprotecting antibody titers as high as in controls after both flu and pneumococcal vaccination [19][20][21]. In addition, no severe collateral effects [19,21,22] and no disease flares were reported [20]. Local and mild side effects in AID, including SSc, are comparable to those in the healthy subject [19,22,23].…”

Section: Efficacy and Safety Of Anti-influenza And Antipneumococcal Vaccinementioning

confidence: 99%

“…While it was debated if vaccination efficacy was comparable to healthy people for rheumatoid arthritis (RA), one of the most common autoimmune disorders, an efficacy as high as in the general population was confirmed for systemic sclerosis. Different studies showed that SSc patients develop seroprotecting antibody titers as high as in controls after both flu and pneumococcal vaccination [19][20][21]. In addition, no severe collateral effects [19,21,22] and no disease flares were reported [20].…”

Section: Efficacy and Safety Of Anti-influenza And Antipneumococcal Vaccinementioning

confidence: 99%

See 2 more Smart Citations

Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic review evaluated the influenza and pneumococcus vaccination coverage for SSc patients. We included all studies from Pubmed reporting on influenza and pneumococcal vaccination rate in Scleroderma patients up to May 2021. The 14 studies thus selected identified a suboptimal vaccination rate in autoimmune and SSc patients, ranging from 28 to 59% for the flu vaccine, and from 11 to 58% for the pneumo vaccine in absence of specific vaccination campaigns, variously considering also other variables such as age, gender, vaccination settings, and possible vaccination campaigns. We also considered the reasons for low coverage and the approaches that might increase the vaccination rates. A lack of knowledge about the importance of vaccination in these patients and their doctors underlined the need to increase the awareness for vaccination in this patients’ category. Current guidelines recommend vaccination in elderly people and people affected by particular conditions that widely overlap with SSc, yet autoimmune diseases are not always clearly mentioned. Improving this suboptimal vaccination rate with clear guidelines is crucial for SSc patients and for clinicians to immunize these categories based principally on the pathology, prior to the age. Recommendations by the immunologist and the direct link to the vaccine providers can highly improve the vaccine coverage.

show abstract

Vaccinations in Patients with Systemic Sclerosis

Bernstein,

Pauling

2024

Scleroderma

View full text Add to dashboard Cite

Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis

Abstract: ClinicalTrials.gov (http://clinicaltrials.gov), NCT01151644.

Cited by 11 publications

References 15 publications

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review

Vaccinations in Patients with Systemic Sclerosis

Contact Info

Product

Resources

About